Platelets, Thromboinflammation and Neurovascular Disease
Ying Sun1,2, Harald F Langer1,2,3
1Cardioimmunology Group, Medical Clinic II, University Heart Center Lübeck, Lübeck, Germany.
Frontiers in Immunology
|March 21, 2022
Summary
Neuroinflammation compromises the blood-brain barrier (BBB), involving microglia and immune cells. Targeting platelets with agents like Anfibatide may reduce inflammation and thrombosis, highlighting interconnected mechanisms for research.
Area of Science:
- Neuroscience
- Immunology
- Pathology
Background:
- The central nervous system (CNS) is immune-privileged, but neuroinflammatory diseases compromise protective barriers like the blood-brain barrier (BBB).
- Microglia and other resident immune cells play a critical role in initiating and propagating neuroinflammation and vascular inflammation.
- These processes can lead to systemic inflammatory responses, impacting overall health.
Purpose of the Study:
- To discuss the activation and response mechanisms of innate and adaptive immunity in neuroinflammation.
- To explore the clinical significance of neuroinflammatory mediators and their translational relevance.
- To highlight the interconnectedness of neuroinflammation and thrombosis, focusing on non-classical immune cells like platelets.
Main Methods:
- Review of innate and adaptive immune processes in neuroinflammation.
- Discussion of clinical importance and translational relevance of neuroinflammatory mediators.
- Examination of novel agents (Anfibatide, Revacept) targeting platelet activation and coagulation.
Main Results:
- Neuroinflammation involves microglia and immune cells disrupting the BBB and promoting vascular inflammation.
- Platelet activation and the coagulation cascade are key components of the inflammatory process in the CNS.
- Novel agents targeting platelets show potential in mitigating neuroinflammation and thrombosis.
Conclusions:
- Neuroinflammation involves complex interactions between immune cells, the BBB, and coagulation pathways.
- Platelets and their interactions are crucial in propagating neuroinflammatory and thrombotic processes.
- Targeting platelet-mediated pathways offers a promising therapeutic strategy for neuroinflammatory and thrombotic disorders.
Related Concept Videos
01:22Formation of the Platelet Plug
7.3K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
7.3K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
959
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
959
01:38Inflammation
55.8K
Overview
55.8K
01:30Venous Thrombosis I: Introduction
52
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
52
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
667
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
667
01:18Structure and Function of Platelets
1.8K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
1.8K